Cogent Biosciences (COGT)
Develops bezuclastinib and other mutation-targeted therapies for mast-cell disease and cancer.
Something off on this page? Send us feedback.
Develops mutation-targeted small-molecule therapies, led by bezuclastinib for systemic mastocytosis and gastrointestinal stromal tumors. Three FDA applications have been submitted, and a newly built U.S. field organization is preparing for potential launches while earlier FGFR2/3, ErbB2, PI3Kα, KRAS, and JAK2 programs expand the pipeline.
Develops precision small-molecule therapies for genetically defined diseases, led by bezuclastinib, a selective KIT inhibitor submitted to the FDA for non-advanced and advanced systemic mastocytosis and, with sunitinib, gastrointestinal stromal tumors. Three applications have been submitted, two with priority review, and a U.S. commercial and medical field organization is in place for potential launches.
Earlier programs include clinical-stage FGFR2/3 inhibitor CGT4859, CNS-penetrant mutant ErbB2 inhibitor CGT4255, and PI3Kα inhibitor CGT6297, plus preclinical KRAS and JAK2 programs. Operations are managed as one segment, with research in Boulder and headquarters in Waltham. The lead asset is licensed from Plexxikon, and the business depends on regulatory decisions and third-party suppliers and manufacturers.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 17, 2026 | Piper Sandler | Reiterate | Rating: —Target: $52 | Target: $55 |
| Aug 12, 2026 | Guggenheim | Reiterate | Rating: —Target: $20 | Target: $52 |
| Jun 1, 2026 | Stifel Nicolaus | Target | Target: $40 | Target: $45 |
| May 6, 2026 | H.C. Wainwright | Target | Target: $52 | Target: $55 |
| Feb 19, 2026 | Robert W. Baird | Target | Target: — | Target: $35 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $792.3M · Total debt $244.3M · Total assets $834.5M · Shareholders' equity $532.4M
- Revenue
- $0
- Operating income
- −$102.6M
- Net income
- −$96.4M
No dividends on record.
| Institutions | ≈ 108.23% | 187.81M shares | |
|---|---|---|---|
| 336 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 6.01% | 10.43M shares | |
| 7 holders · as of May 21, 2026 | |||
| Adds to | 114.24% | ||
173.52M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 114.24%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 14.80% | 25.68M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 10.00% | 17.35M | as of Jun 30, 2026 |
Deerfield Mgmt, L.P.Insider | 5.21% | 9.04M | filed May 14, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.65% | 8.07M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.27% | 7.41M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 27, 2026 | Arlene Morris | director | −45,510 | $37.12 |
| Mar 31, 2026 | Fairmount Funds Management LLC | director | −7,000,000 | $34.66 |
| Jan 22, 2026 | Fairmount Funds Management LLC | director | −3,500,000 | $36.40 |
| Dec 26, 2025 | John Edward Robinson | officer: Chief Scientific Officer | −90,000 | $38.74 |
| Dec 26, 2025 | Jessica Sachs | officer: Chief Medical Officer | −82,642 | $38.70 |
- Sanofi (ADR)
Approved SM therapy and KIT pipeline pressure
- Novartis (ADR)
Established SM and GIST standards of care
- Pfizer
Second-line GIST benchmark through Sutent
- GSK (ADR)
Emerging second-line GIST pipeline pressure
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cogent Biosciences | $31.18 | −4.46% | $5.58B | — | — | — | — |
| Sanofi (ADR) | $41.50 | −2.39% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Novartis (ADR) | $142.63 | +0.95% | $268.53B | 21.3 | 15.2 | 4.8 | +0.9% |
| Pfizer | $27.92 | −0.04% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| GSK (ADR) | $49.74 | −1.93% | $101.62B | 16.1 | 9.2 | 2.3 | +5.3% |
| Median | 29.1 | 10.0 | 2.4 | +4.0% |